Novavax, Inc. (NVAX): Price and Financial Metrics


Novavax, Inc. (NVAX): $248.16

-9.14 (-3.55%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add NVAX to Watchlist
Sign Up

Industry: Biotech


Ranked

of 505

in industry

NVAX POWR Grades


  • Value is the dimension where NVAX ranks best; there it ranks ahead of 84.12% of US stocks.
  • NVAX's strongest trending metric is Momentum; it's been moving down over the last 48 weeks.
  • NVAX ranks lowest in Stability; there it ranks in the 1st percentile.

NVAX Stock Summary

  • Of note is the ratio of Novavax Inc's sales and general administrative expense to its total operating expenses; merely 5.04% of US stocks have a lower such ratio.
  • In terms of twelve month growth in earnings before interest and taxes, Novavax Inc is reporting a growth rate of 1,060.38%; that's higher than 97.64% of US stocks.
  • Revenue growth over the past 12 months for Novavax Inc comes in at 2,252.66%, a number that bests 99.48% of the US stocks we're tracking.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Novavax Inc are FIXX, GRTS, OVID, DNLI, and ADVM.
  • NVAX's SEC filings can be seen here. And to visit Novavax Inc's official web site, go to www.novavax.com.

NVAX Valuation Summary

  • In comparison to the median Healthcare stock, NVAX's price/earnings ratio is 151.23% lower, now standing at -18.7.
  • NVAX's price/sales ratio has moved down 7.3 over the prior 243 months.
  • NVAX's price/sales ratio has moved down 7.3 over the prior 243 months.

Below are key valuation metrics over time for NVAX.

Stock Date P/S P/B P/E EV/EBIT
NVAX 2021-08-31 15.0 23.8 -18.7 -17.4
NVAX 2021-08-30 14.7 23.3 -18.3 -17.0
NVAX 2021-08-27 14.3 22.6 -17.8 -16.4
NVAX 2021-08-26 14.5 23.0 -18.1 -16.7
NVAX 2021-08-25 15.0 23.8 -18.7 -17.4
NVAX 2021-08-24 14.7 23.3 -18.3 -16.9

NVAX Growth Metrics

  • Its year over year price growth rate is now at 555.1%.
  • Its 5 year net income to common stockholders growth rate is now at -5.16%.
  • Its 4 year net cashflow from operations growth rate is now at 34.04%.
Over the past 33 months, NVAX's revenue has gone up $1,143,356,000.

The table below shows NVAX's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-06-30 1,181.929 672.432 -949.91
2021-03-31 919.45 643.654 -615.114
2020-12-31 475.598 -42.541 -418.259
2020-09-30 204.755 62.284 -272.525
2020-06-30 50.238 36.522 -93.258
2020-03-31 18.057 -109.126 -115.34

NVAX's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • NVAX has a Quality Grade of C, ranking ahead of 58.9% of graded US stocks.
  • NVAX's asset turnover comes in at 0.6 -- ranking 58th of 677 Pharmaceutical Products stocks.
  • GTHX, SRRA, and OPK are the stocks whose asset turnover ratios are most correlated with NVAX.

The table below shows NVAX's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.600 1 -14.595
2021-03-31 0.606 1 -1.737
2020-12-31 0.502 1 -0.781
2020-09-30 0.345 1 -0.602
2020-06-30 0.126 1 -0.222
2020-03-31 0.084 1 -0.295

NVAX Price Target

For more insight on analysts targets of NVAX, see our NVAX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $264.20 Average Broker Recommendation 1.58 (Moderate Buy)

NVAX Stock Price Chart Interactive Chart >

Price chart for NVAX

NVAX Price/Volume Stats

Current price $248.16 52-week high $331.68
Prev. close $257.30 52-week low $76.59
Day low $246.25 Volume 3,007,100
Day high $257.30 Avg. volume 4,412,690
50-day MA $226.33 Dividend yield N/A
200-day MA $194.55 Market Cap 18.48B

Novavax, Inc. (NVAX) Company Bio


Novavax, Inc. focuses on discovering, developing, and commercializing recombinant nanoparticle vaccines and adjuvants. The company was founded in 1987 and is based in Gaithersburg, Maryland.


NVAX Latest News Stream


Event/Time News Detail
Loading, please wait...

NVAX Latest Social Stream


Loading social stream, please wait...

View Full NVAX Social Stream

Latest NVAX News From Around the Web

Below are the latest news stories about Novavax Inc that investors may wish to consider to help them evaluate NVAX as an investment opportunity.

Novavax, Serum seek emergency use approval from WHO for Covid vaccine

Novavax and SII made regulatory submissions to WHO for EUL of Novavaxs recombinant nanoparticle protein-based Covid-19 vaccine candidate with Matrix-M adjuvant.

The Financial Express | September 24, 2021

‘I don’t think we’ve done enough to get vaccines overseas’: Doctor

Dr. Arthur Caplan, NYU Langone Health, Division of Medical Ethics at NYU School of Medicine, joins Yahoo Finance to discuss the latest on the coronavirus vaccines and booster shots.

Yahoo | September 24, 2021

Novavax just took a big step to get its Covid vaccine to the world — and the stock surged

The company is still working to submit its vaccine candidate to U.S. authorities for federal approval.

Yahoo | September 24, 2021

Novavax (NVAX) Applies to WHO for COVID-19 Vaccine Listing

On being granted the emergency use listing for Novavax's (NVAX) COVID-19 vaccine by WHO, it is to become eligible to supply the same to numerous countries participating through the COVAX facility

Yahoo | September 24, 2021

Novavax Hosts HM King Carl XVI Gustaf and HM Queen Silvia of Sweden During Royal Visit to Uppsala County

Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, hosted HM King Carl XVI Gustaf and HM Queen Silvia for a visit to Novavax AB, the company's Uppsala, Sweden manufacturing affiliate on Thursday, September 23. The visit included a discussion of NVX-CoV2373, Novavax' recombinant nanoparticle protein-based COVID-19 vaccine candidate, and the company's role in combatting the global pandemic.

Yahoo | September 24, 2021

Read More 'NVAX' Stories Here

NVAX Price Returns

1-mo 7.74%
3-mo 30.76%
6-mo 42.83%
1-year 118.53%
3-year 574.35%
5-year 428.00%
YTD 122.55%
2020 2,701.76%
2019 -89.18%
2018 48.39%
2017 -1.59%
2016 -84.98%

Continue Researching NVAX

Want to see what other sources are saying about Novavax Inc's financials and stock price? Try the links below:

Novavax Inc (NVAX) Stock Price | Nasdaq
Novavax Inc (NVAX) Stock Quote, History and News - Yahoo Finance
Novavax Inc (NVAX) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 1.0973 seconds.